US 2019/0315864 A1Published application

Single domain antibody and derivative proteins thereof against ctla4

AssigneesSuzhou Alphamab Co., Ltd., Xitian Zhang, Xin Zhang

InventorsTing Xu, Xiaoxiao Wang, Jie Li, Haiyan Wu, Li Gao, Qian Chu, Yu Bai

Life of this patent

Estimating the term…

Abstract

The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

Claims27

Dependent claims

A CTLA4-binding protein, which can specifically bind to CTLA4 and comprises at least one immunoglobulin single variable domain, said immunoglobulin single variable domain comprises CDR1, CDR2 and CDR3 selected from:

(1) CDR1 set forth in SEQ ID NO:1, CDR2 set forth in SEQ ID NO:2, CDR3 set forth in SEQ ID NO:3;
(2) CDR1 set forth in SEQ ID NO:4, CDR2 set forth in SEQ ID NO:5, CDR3 set forth in SEQ ID NO:6;
(3) CDR1 set forth in SEQ ID NO:7, CDR2 set forth in SEQ ID NO:8, CDR3 set forth in SEQ ID NO:9;
(4) CDR1 set forth in SEQ ID NO:10, CDR2 set forth in SEQ ID NO:11, CDR3 set forth in SEQ ID NO:12;
(5) CDR1 set forth in SEQ ID NO:13, CDR2 set forth in SEQ ID NO:14, CDR3 set forth in SEQ ID NO:15;
(6) CDR1 set forth in SEQ ID NO:16, CDR2 set forth in SEQ ID NO:17, CDR3 set forth in SEQ ID NO:18;
(7) CDR1 set forth in SEQ ID NO:19, CDR2 set forth in SEQ ID NO:20, CDR3 set forth in SEQ ID NO:21;
(8) CDR1 set forth in SEQ ID NO:22, CDR2 set forth in SEQ ID NO:23, CDR3 set forth in SEQ ID NO:24;
(9) CDR1 set forth in SEQ ID NO:25, CDR2 set forth in SEQ ID NO:26, CDR3 set forth in SEQ ID NO:27;
(10) CDR1 set forth in SEQ ID NO:28, CDR2 set forth in SEQ ID NO:29, CDR3 set forth in SEQ ID NO:30;
(11) CDR1 set forth in SEQ ID NO:31, CDR2 set forth in SEQ ID NO:32, CDR3 set forth in SEQ ID NO:33;
(12) CDR1 set forth in SEQ ID NO:34, CDR2 set forth in SEQ ID NO:35, CDR3 set forth in SEQ ID NO:36;
(13) CDR1 set forth in SEQ ID NO:37, CDR2 set forth in SEQ ID NO:38, CDR3 set forth in SEQ ID NO:39;
(14) CDR1 set forth in SEQ ID NO:40, CDR2 set forth in SEQ ID NO:41, CDR3 set forth in SEQ ID NO:42;
(15) CDR1 set forth in SEQ ID NO:43, CDR2 set forth in SEQ ID NO:44, CDR3 set forth in SEQ ID NO:45;
(16) CDR1 set forth in SEQ ID NO:46, CDR2 set forth in SEQ ID NO:47, CDR3 set forth in SEQ ID NO:48;
(17) CDR1 set forth in SEQ ID NO:49, CDR2 set forth in SEQ ID NO:50, CDR3 set forth in SEQ ID NO:51;
(18) CDR1 set forth in SEQ ID NO:52, CDR2 set forth in SEQ ID NO:53, CDR3 set forth in SEQ ID NO:54;
(19) CDR1 set forth in SEQ ID NO:55, CDR2 set forth in SEQ ID NO:56, CDR3 set forth in SEQ ID NO:57;
(20) CDR1 set forth in SEQ ID NO:58, CDR2 set forth in SEQ ID NO:59, CDR3 set forth in SEQ ID NO:60;
(21) CDR1 set forth in SEQ ID NO:61, CDR2 set forth in SEQ ID NO:62, CDR3 set forth in SEQ ID NO:63;
(22) CDR1 set forth in SEQ ID NO:64, CDR2 set forth in SEQ ID NO:65, CDR3 set forth in SEQ ID NO:66;
(23) CDR1 set forth in SEQ ID NO:67, CDR2 set forth in SEQ ID NO:68, CDR3 set forth in SEQ ID NO:69;
(24) CDR1 set forth in SEQ ID NO:70, CDR2 set forth in SEQ ID NO:71, CDR3 set forth in SEQ ID NO:72;
and
(25) CDR1 set forth in SEQ ID NO:73, CDR2 set forth in SEQ ID NO:74, CDR3 set forth in SEQ ID NO:75.

23 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/302,583Filed 19 May 2017
Priority: CN 201610332590.719 May 2016
Published: 17 Oct 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification43 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens

Family

US 11,091,549 B2Related patent
US 2019/0315864 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

(1) CDR1 set forth in SEQ ID NO:1, CDR2 set forth in SEQ ID NO:2, CDR3 set forth in SEQ ID NO:3;
(2) CDR1 set forth in SEQ ID NO:4, CDR2 set forth in SEQ ID NO:5, CDR3 set forth in SEQ ID NO:6;
(3) CDR1 set forth in SEQ ID NO:7, CDR2 set forth in SEQ ID NO:8, CDR3 set forth in SEQ ID NO:9;
(4) CDR1 set forth in SEQ ID NO:10, CDR2 set forth in SEQ ID NO:11, CDR3 set forth in SEQ ID NO:12;
(5) CDR1 set forth in SEQ ID NO:13, CDR2 set forth in SEQ ID NO:14, CDR3 set forth in SEQ ID NO:15;
(6) CDR1 set forth in SEQ ID NO:16, CDR2 set forth in SEQ ID NO:17, CDR3 set forth in SEQ ID NO:18;
(7) CDR1 set forth in SEQ ID NO:19, CDR2 set forth in SEQ ID NO:20, CDR3 set forth in SEQ ID NO:21;
(8) CDR1 set forth in SEQ ID NO:22, CDR2 set forth in SEQ ID NO:23, CDR3 set forth in SEQ ID NO:24;
(9) CDR1 set forth in SEQ ID NO:25, CDR2 set forth in SEQ ID NO:26, CDR3 set forth in SEQ ID NO:27;
(10) CDR1 set forth in SEQ ID NO:28, CDR2 set forth in SEQ ID NO:29, CDR3 set forth in SEQ ID NO:30;
(11) CDR1 set forth in SEQ ID NO:31, CDR2 set forth in SEQ ID NO:32, CDR3 set forth in SEQ ID NO:33;
(12) CDR1 set forth in SEQ ID NO:34, CDR2 set forth in SEQ ID NO:35, CDR3 set forth in SEQ ID NO:36;
(13) CDR1 set forth in SEQ ID NO:37, CDR2 set forth in SEQ ID NO:38, CDR3 set forth in SEQ ID NO:39;
(14) CDR1 set forth in SEQ ID NO:40, CDR2 set forth in SEQ ID NO:41, CDR3 set forth in SEQ ID NO:42;
(15) CDR1 set forth in SEQ ID NO:43, CDR2 set forth in SEQ ID NO:44, CDR3 set forth in SEQ ID NO:45;
(16) CDR1 set forth in SEQ ID NO:46, CDR2 set forth in SEQ ID NO:47, CDR3 set forth in SEQ ID NO:48;
(17) CDR1 set forth in SEQ ID NO:49, CDR2 set forth in SEQ ID NO:50, CDR3 set forth in SEQ ID NO:51;
(18) CDR1 set forth in SEQ ID NO:52, CDR2 set forth in SEQ ID NO:53, CDR3 set forth in SEQ ID NO:54;
(19) CDR1 set forth in SEQ ID NO:55, CDR2 set forth in SEQ ID NO:56, CDR3 set forth in SEQ ID NO:57;
(20) CDR1 set forth in SEQ ID NO:58, CDR2 set forth in SEQ ID NO:59, CDR3 set forth in SEQ ID NO:60;
(21) CDR1 set forth in SEQ ID NO:61, CDR2 set forth in SEQ ID NO:62, CDR3 set forth in SEQ ID NO:63;
(22) CDR1 set forth in SEQ ID NO:64, CDR2 set forth in SEQ ID NO:65, CDR3 set forth in SEQ ID NO:66;
(23) CDR1 set forth in SEQ ID NO:67, CDR2 set forth in SEQ ID NO:68, CDR3 set forth in SEQ ID NO:69;
(24) CDR1 set forth in SEQ ID NO:70, CDR2 set forth in SEQ ID NO:71, CDR3 set forth in SEQ ID NO:72;
and
(25) CDR1 set forth in SEQ ID NO:73, CDR2 set forth in SEQ ID NO:74, CDR3 set forth in SEQ ID NO:75.

23 more elements

Facts

Application

16/302,583Filed 19 May 2017

Priority

CN 201610332590.719 May 2016

Published

17 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification43 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens